Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Carcinoma × Albumin-Bound Paclitaxel × 90 days × Clear all

Phase

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Tumor-Agnostic 1

Conditions

Pancreatic Neoplasms 14 Triple Negative Breast Neoplasms 8 Carcinoma, Non-Small-Cell Lung 6 Breast Neoplasms 6 Parkinson Disease 4, Autosomal Dominant Lewy Body 5 Lung Neoplasms 5 Squamous Cell Carcinoma of Head and Neck 3 Neoplasm Metastasis 3 Rectal Neoplasms 2 Fallopian Tube Neoplasms 2 Esophageal Squamous Cell Carcinoma 2 Endometrial Neoplasms 2 Colorectal Neoplasms 2 Colonic Neoplasms 2 Carcinoma, Pancreatic Ductal 2 Thyroid Neoplasms 1 Thyroid Carcinoma, Anaplastic 1 Stomach Neoplasms 1 Solid Cancer 1 Recurrence 1 Pancreatic Adenocarcinoma 1 Ovarian Neoplasms 1 Oropharyngeal Neoplasms 1 Non-Small-Cell Lung 1 Non-Small Cell Lung Cancer Metastatic 1 Non Small Cell Lung Cancer NSCLC 1 Neoplasms 1 Mouth Neoplasms 1 Metastatic Adenocarcinoma of the Pancreas 1 Lip Neoplasms 1

Interventions

pembrolizumab 16 Magnetic Resonance Spectroscopy 13 Specimen Handling 12 Cisplatin 12 Carboplatin 9 Paclitaxel 8 Radiotherapy, Intensity-Modulated 6 Platinum 6 Cetuximab 6 1,2-diaminocyclohexaneplatinum II citrate 6 Biopsy 5 durvalumab 4 Pemetrexed 4 (225)Ac-DOTA-c(RGDyK) 4 osimertinib 3 Taxes 3 Radiotherapy 3 Radiation 3 Immunoglobulin G 3 Gemcitabine 3 Disulfides 3 1-(1-(imidazo(1,2-a)pyridin-6-yl)ethyl)-6-(1-methyl-1H-pyrazol-4-yl)-1H-(1,2,3)triazolo(4,5-b)pyrazine 3 olaparib 2 ipatasertib 2 cemiplimab 2 cabozantinib 2 Tadalafil 2 Nivolumab 2 Ipilimumab 2 Fluorouracil 2

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT03976362 2026-02-25

KEYLYNK-008

Merck Sharp & Dohme LLC

Phase 3 Completed

851 enrolled 25 charts

Carcinoma

Data powered by HemOnc (CC BY 4.0) Colophon ⚡